Investor Presentation

gaudium |VF Delivering Motherhood Dreams August 14, 2026 National Stock Exchange of India Limited BSE Limited i j bhoy T s, Dalal Exchange Plaza, C--11, , Bl Block G. 3 gl;;;gtz eFJOer?ee o o Bandra Kurla Complex, Bandra (E), Mumbaii — 400001, Maharashtra Mumbaii —— 400040500151,, Maharashtra Symbol - GAUDIUMIVF Scrip Code — 544709 ISIN: INEOP8B01020 ISIN: INEOP8B01020 Dear Sir/Madam, Subject: Revised Investor Presentation on the Financial Results of the Company for the quarter ended June 30. 2026 With reference to our earlier intimation dated August 13, 2026, regarding submission of the Investor Presentation on the financial results of the Company for the quarter ended June 30, 2026, pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that certain corrections and additional disclosures have been incorporated in the Investor Presentation submitted earlier. The following changes have been made to the Revised Investor Presentation: 1. Slide No. 25 — Financial Statement (Standalone): -Addition of the disclosure: “Major Expense being one time marketing cost of Rs. 253.24 lakhs of SID and ERICA.” -Correction of the disclosure relating to Adjusted EBITDA to read as: “Adjusted EBITDA is Rs. 507.75 lakhs being 37.12% EBITDA margin.” 2. Slide No. 26 — Financial Statement (Consolidated): -Addition of the disclosure: “Major Expense being one time marketing cost of Rs. 253.24 lakhs of SID and ERICA.” -Correction oft he disclosure relating to Adjusted EBITDA to read as: “Adjusted EBITDA is Rs. 532.75 lakhs being 27.49% EBITDA margin.” In this regard, we are enclosing herewith the Revised Investor Presentation incorporating the aforesaid additional disclosure. The Revised Investor Presentation supersedes the Investor Presentation filed with the Stock Exchanges on August 13, 2026. This disclosure will also be hosted on the website of the Company at www.gaudiumivfcentre.com. Kindly take the information on record. Thanking you, Yours faithfully. For and on behalf of Gaudium IVF and Women Health Limited (Formerly known as Gaudium IVF and Women Health Private Limited) Naveen Kumar Company Secretary and Compliance Officer Membership No.: A69788 Encl.: a/a Gaudium IVF and Women Health Limited (Formerly known as Gaudium IVF and Women Health Pvt. Ltd.) Registered Office : B1/51, Janakpuri, New Delhi- 110058 | Ph: 011-4885 8585 CIN : L85100DL2015PLC278296 Email : info@gaudiumivfcentre.com Website : www.gaudiumivfcentre.com [El4t GAUDIUM IVF and WOMEN HEALTH LTD. INVESTOR PRESENTATION Q1 FY27 Safe Harbour This document is prepared only for information purpose and do not solicit/recommend/guide for any Investment/Buy-Sell in any financial instrument of Gaudium IVF and Women Health Limited (“Gaudium”) and/or any of its subsidiary company or associate company. Neither Gaudium nor any of its group company/subsidiary Company/ associate company , directors, or employees related person are responsible for any gains/loss arising to any person/body corporate due to any such transaction as stated above. This document may contain certain forward-looking statements. These forward-looking statements can generally be identified by words or phrases such as “aim”, “anticipate”, “believe”, “expect”, “estimate”, “intend”, “objective”, “plan”, “project”, “shall”, “will”, “will continue”, “will pursue” or other words or phrases of similar meaning. Similarly, statements that describe strategies, objectives, plans or goals are also forward-looking statements. Gaudium cannot assure investors that the expectation reflected in these forward-looking statements will prove to be correct. Given these uncertainties, investors are cautioned not to place undue reliance on such forward- looking statements and not to regard such statements as a guarantee of future performance. Table of Contents 01 02 03 04  CompanyataGlance  IVFIndustryOverview  Center/HubWiseDetails  FinancialSnapshot  ShareholdingPattern &KeyMarketData  JourneyofGaudiumIVF  GrowthDriversinthe  AIThatMakesthe  Q1FY27StandaloneP&L Industry Difference  CaseStudies  ProcessFlow-IVF  Q1FY27ConsolidatedP&L Treatment  EntryBarriersinIndustry  Infrastructure&Facilities  Awardsand atCenters Recognitions  AI-PoweredEnd-to-End  OurMoat,OurMomentum FertilitySolutions  360°CustomerAcquisition  CSRInitiatives  Pan-IndiaPresence  KeyClinicalHighlights  RapidGrowthStrategy  PatientTestimonials  ServingPatientsAround  StrategicMilestones TheGlobe  BoardOfDirectors ABOUT US Company at a Glance Founded: March 2015 by Dr Manika Khanna and Dr. Peeyush Khanna Network: 8 Hubs + 28 Spokes | Presence: 9 States across India Services Revenue Split AI Initiatives to help improve success rate: SiD & ERICA 29.41% 4.35% Success Rates: Success Rates: 62% 85% First Attempt - Multiple Attempts - 66.24% No of OPU: 367 Average Revenue Per Patient: Rs. 3.5 lakhs IVFTreatment Hospital Pharmacy Journey of Gaudium IVF 2009 2016 2017 2019 Janakpuri Greater Ludhiana Patna Hub Hub Kailash Hub Hub SpokesatBihar, Srinagar&Punjab 2026 2024 2023 2022 BSE & NSE Listing Srinagar Hub Bangalore Hub Mumbai Hub South Delhi Hub SpokesatMumbai Gurgaon&Nagpur (Underconstruction Stage) Process Flow - IVF Treatment A seamless, patient-centric journey supported by clinical excellence and care at every step 1 ConversionofLead 2 IVFProcessStarts 3 Hospital&PostCare Injections Success/ LeadGenerated Packageamounteither FailureofET &Followup paidinfullorininstallment asperthepaymentterms (Capturedinpatientfile) DeliveryPackage IfNegative IfPositive (pricingvariesbasis OvumPickUp(OPU) roomcategory. ~70%ofthepackage amountiscollectedbyOPU LeadRe-engaged PatientWalk-in SubsequentThaw ET-Separate RoutineSupport(from Successful package month4-9,including RegistrationofPatient, vaccinesetc) Insemination& FreeOPDandUltrasound EmbryoFormation Incaseof IfInterested miscarriage Supportavailableonlyat DelhiJanakpuriCentre Discussionwithfinance IVF counseloronpackage Embryo Successful FreezeAll Transfer(ET) andpaymentterms AI-Powered End-to-End Fertility Solutions Advanced IVF Male Infertility Ovulation Induction Egg Freezing ERICA SiD Treatment Infertility Surgeries Frozen Embryo Embryo Freezing Gynae Laparoscopy for PCOD/PCOS Transfer Consultation Infertility Key Clinical Highlights SOP-Driven Organization AI-Powered IVF In-House Trained Talent From clinical, embryology and doctors to First in India, 2nd outside the US to Clinicians and embryologists trained within housekeeping. introduce AI tools SID & ERICA. Gaudium. Signature Labs & IVF MANTRANA Constant Innovation State-of-the-art Gaudium Signature Dedicated emotional counselling support Especially for patients with multiple failed IVFs. laboratories and IVF. for patients. ART Law Compliance Global Patient Base Strict adherence to the ART (Regulation) Act. Successfully treated patients from 30+ countries. Success rate at one attempt; early results show an 8–9% increase with SID & ERICA. Strategic Milestones India's First India's No. 1 IVF company to be listed on the stock IVF Clinic ranking as per the Health Survey market, marking a historic milestone in the conducted by Times of India. fertility care industry. India's First India's First IVF chain to introduce Artificial Intelligence in IVF company to receive the European Quality infertility treatment. Award for the highest quality standard. BUSINESS OVERVIEW IVF Industry Overview Strong demographic tailwinds, significant treatment gap and evolving industry structure create a long runway for scalable growth MARKET SIZE & GROWTH SIGNIFICANT UNDERPENETRATION STRUCTURAL SUPPLY GAP IndiaIVFMarketSize(USDBillion) Hugegapbetweenneedandtreatment IVFaccessremains 4.54 concentratedin Top 8 Metro cities DelhiNCR,Mumbai, 1.32 13.1% Ahmedabad,Chennai, CAGR ~27.5 Mn ~300,000 Kolkata,Hyderabad, Infertilecouples IVFcycles Bengaluru,Pune inIndia annually 2024 2034E GlobalIVFmarketprojectedtogrowfrom Ind [Showing first 8,000 characters — download PDF for full document]